Last reviewed · How we verify

NCT05299905

ImGTS for Patients With Cerebral Palsy and With Mobility Limitations

Completed NA Last updated 1 February 2023
What this trial tests

NA trial testing Virtual reality using Semi-CAVE in Cerebral Palsy in 30 participants. Completed in 22 July 2022.

Timeline
28 April 2022
Primary endpoint
22 July 2022
22 July 2022

Quick facts

Lead sponsorAugmented eXperience E-health Laboratory
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposeother
Enrollment30
Start date28 April 2022
Primary completion22 July 2022
Estimated completion22 July 2022
Sites1 location across Philippines

Drugs / interventions tested

Conditions studied

Sponsor

Augmented eXperience E-health Laboratory

Who can join

Adults 6 to 12, any sex, with Cerebral Palsy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The proposed research project aims to answer the question "Are immersive technology systems effective in the rehabilitation management of pediatric patients with cerebral palsy and with mobility limitations?". The current study is the first of three phases, and it aims to create an immersive gamification technology system for the management of patients with cerebral palsy and with mobility disorders and to determine its acceptability, usability, and safety in healthy children.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Cerebral Palsy

Currently open trials in the same condition.

Other Augmented eXperience E-health Laboratory trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05299905.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing